ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
28 announcements with these filters
Kopran Limited responded to NSE's price-movement query stating no material information was withheld. The stock's rise is attributed to purely market-driven forces.
Kopran Limited allotted 40,500 equity shares to employees under its ESOP 2023 scheme. The exercise price for these shares is Rs 179 per share.
United Shippers, a promoter of Kopran, sold 12,00,000 shares in the open market on 07 Sept 2026. Its stake fell from 4.56% to 2.07%.
Kopran Limited clarified to NSE that the recent increase in trading volume is purely market-driven. The company confirmed it has not withheld any material price-sensitive information.
Kopran Ltd held its 67th Annual General Meeting on August 18, 2026, where all items were passed. Voting results and the Scrutinizer's Report were submitted.
Kopran Ltd reported Q1 FY27 revenue of ₹15,399 Lakhs with a 10.31% EBITDA margin, focusing on API and Formulation verticals across 50+ nations.
Kopran Ltd reported revenue from operations of ₹154 Cr (+13.9% YoY) and net profit of ₹6.7 Cr (-9.5% YoY) for Q1 FY27.
Kopran Ltd has submitted its Annual Report for FY 2025-26, including the notice of its 67th Annual General Meeting scheduled for August 18, 2026.
Kopran Ltd has scheduled a board meeting for August 07, 2026, to consider and approve its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
Kopran Limited fixed August 11, 2026, as the record date for dividend payments. The dividend is subject to approval at the AGM scheduled for August 18, 2026.
Kopran Limited appointed Mr. Vijay L Thange as Chief Technical Officer. He brings over 36 years of experience in the pharma sector.
Kopran Limited shareholders and creditors approved the Scheme of Amalgamation with Kopran Laboratories Limited. The resolution passed with requisite majority during the NCLT-convened meetings.
Kopran Ltd submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory adherence with no significant non-compliances.
Kopran Limited recommended a final dividend of ₹3 per equity share for FY 2025-26. Shareholders will vote for approval at the upcoming August 18 general meeting.
Kopran Ltd reported highest-ever quarterly revenue of ₹23,402 lakhs and EBITDA of ₹4,057 lakhs in Q4-FY26, driven by strong growth in APIs and Formulations.
Kopran Limited appointed Mrs. Namrata Varun Somani as a Non-Executive Director for five years. This strategic board addition strengthens leadership and brings legal expertise.
Kopran Ltd reported revenue from operations of ₹234 Cr (+35.7% YoY) and net profit of ₹18.9 Cr (+94.8% YoY) for Q4 FY26.
Kopran Limited reported audited FY2026 financial results and recommended a ₹3.00 per share dividend. The board also appointed Namrata Somani as a non-executive promoter group director.
Kopran's subsidiary KRLL will raise ₹18.75 Crore through a 1:12 rights issue. Proceeds will fund working capital requirements, strengthening the subsidiary's operational liquidity.
Kopran Limited announced an NCLT-convened meeting on June 3, 2026, to approve the amalgamation of Kopran Laboratories Limited into the company. The merger will increase promoter shareholding from 44.43% to 55.33%. This consolidation aims to streamline the group structure and enhance operational efficiencies in the pharmaceutical and healthcare segments.
Kopran Ltd has scheduled a Board Meeting on May 19, 2026, to approve audited financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a dividend. The trading window for company securities remains closed until 48 hours after the results declaration.
Kopran Limited announced meetings for shareholders and creditors on June 03, 2026, to approve the merger by absorption of Kopran Laboratories Limited. The amalgamation is pursuant to an NCLT Mumbai Bench order dated April 09, 2026. This consolidation aims to merge the transferor entity into the transferee company.
Kopran Ltd reported net profit of ₹9.3 Cr (-10.6% YoY) for Q3 FY26.
Kopran Limited received an NCLT order dated April 09, 2026, directing the company to hold meetings for Equity Shareholders, Secured Creditors, and Unsecured Creditors. This update relates to the ongoing Scheme of Amalgamation of Kopran Laboratories Limited with Kopran Limited.
Kopran Limited clarified to NSE that recent significant share price movement is purely market-driven. The company confirmed compliance with SEBI Regulation 30, stating no material information or events affecting the price have been withheld from the exchanges.
Kopran Ltd clarified to BSE that the recent significant movement in its share price is purely market-driven. The company confirmed it has made all required disclosures under SEBI Regulation 30 and has not withheld any price-sensitive information.
Kopran Ltd clarified to the BSE that the recent increase in its stock's trading volume is purely market-driven. The company confirmed it has disclosed all material information under SEBI regulations and is not aware of any undisclosed events impacting the volume movement.
Kopran Limited clarified to the NSE that the recent significant increase in trading volume is purely market-driven. The company confirmed it has made all required disclosures under SEBI Regulations and is not withholding any material information that could impact the scrip's volume.